Search research articles
Contact Us
Filters
Showing results (331-340 of 483) with videos related to
Page
of 49
Sort By:
Journal of Clinical Microbiology
|
December 28, 2012
Utility of PCR in diagnosis of invasive fungal infections: real-life data from a multicenter study
Cornelia Lass-Flörl, Wolfgang Mutschlechner, Maria Aigner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 8, 2021
Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)
J Randolph Hecht, Sara Lonardi, Johanna Bendell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 22, 2007
Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14
Günther G Steger, Arik Galid, Michael Gnant, et al.
Blood
|
May 31, 2023
Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studies
Dennis A Eichenauer, Ina Bühnen, Christian Baues, et al.
Haematologica
|
November 13, 2025
Thrombin generation to predict breakthrough bleeding in patients with acquired hemophilia A under emicizumab prophylaxis
Fabius J Pelzer, Ella I Ertekin, Olga Oleshko, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 25, 2012
Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial
Bastian von Tresckow, Annette Plütschow, Michael Fuchs, et al.
Hemasphere
|
November 15, 2019
Reduced-Intensity Chemotherapy in Patients With Advanced-Stage Hodgkin Lymphoma: Updated Results of the Open-Label, International, Randomised Phase 3 HD15 Trial by the German Hodgkin Study Group
Andreas Engert, Helen Goergen, Jana Markova, et al.
Anticancer Research
|
October 3, 2022
Retrospective Analysis of Treatment Pathways in Patients With BRAF<sup>V600E</sup>-mutant Metastatic Colorectal Carcinoma - MORSE<sup>CRC</sup>
Armin Gerger, Wolfgang Eisterer, Stefan Fuxius, et al.
The Lancet. Oncology
|
August 10, 2016
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial
Christoph Zielinski, István Láng, Moshe Inbar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 12, 2021
The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8
Martin Filipits, Margaretha Rudas, Verena Kainz, et al.
Page
of 49
Search research articles
Search
Showing results (331-340 of 483) with videos related to
Sort By:
Page
of 49
Journal of Clinical Microbiology
|
December 28, 2012
Utility of PCR in diagnosis of invasive fungal infections: real-life data from a multicenter study
Cornelia Lass-Flörl, Wolfgang Mutschlechner, Maria Aigner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 8, 2021
Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)
J Randolph Hecht, Sara Lonardi, Johanna Bendell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 22, 2007
Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14
Günther G Steger, Arik Galid, Michael Gnant, et al.
Blood
|
May 31, 2023
Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studies
Dennis A Eichenauer, Ina Bühnen, Christian Baues, et al.
Haematologica
|
November 13, 2025
Thrombin generation to predict breakthrough bleeding in patients with acquired hemophilia A under emicizumab prophylaxis
Fabius J Pelzer, Ella I Ertekin, Olga Oleshko, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 25, 2012
Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial
Bastian von Tresckow, Annette Plütschow, Michael Fuchs, et al.
Hemasphere
|
November 15, 2019
Reduced-Intensity Chemotherapy in Patients With Advanced-Stage Hodgkin Lymphoma: Updated Results of the Open-Label, International, Randomised Phase 3 HD15 Trial by the German Hodgkin Study Group
Andreas Engert, Helen Goergen, Jana Markova, et al.
Anticancer Research
|
October 3, 2022
Retrospective Analysis of Treatment Pathways in Patients With BRAF<sup>V600E</sup>-mutant Metastatic Colorectal Carcinoma - MORSE<sup>CRC</sup>
Armin Gerger, Wolfgang Eisterer, Stefan Fuxius, et al.
The Lancet. Oncology
|
August 10, 2016
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial
Christoph Zielinski, István Láng, Moshe Inbar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 12, 2021
The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8
Martin Filipits, Margaretha Rudas, Verena Kainz, et al.
Page
of 49